Medication for Cardiovascular Disease

In the U.S. someone has a heart attack or stroke every 40 seconds,1 and nearly one in three of these patients will have another cardiovascular (CV) event. Seth J. Baum, M.D., joins us from the American College of Cardiology’s (ACC) 67th Annual Scientific Sessions to discuss new research that explores the clinical impact for cardiovascular patients denied access to PCSK9 inhibitors. He also touches on the significant need to ensure high-risk patients – people with high ‘bad’ cholesterol and those at risk for a cardiovascular event – who may benefit from a PCSK9 inhibitor can receive it if appropriately prescribed by their physicians. 

Print this article Back to Top